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CD10 isa cell surface zinc-dependent endopeptidase, whichdegrades many bioactive peptides. CD10 expressionintumour stroma
is associated with biologicalaggressiveness of many epithelial malignancies.To date, only one study has correlated with expression of
CD10 with well-known prognostic markers of breast, that is, ER, PR, HER2-neu, and tumour grade; however, its correlation with ki67
is still not studied. The aim of this study is to evaluate stromal CD10 expression in breast carcinoma and to examine its correlation
with ER, PR, HER2-neu, and Ki67. Methods and Results. CD10 expression in ﬁfty patients was assessed by immunohistochemistry
and scored as negative, weak and strong. CD10 was found to be positive in stroma of 40/50 (80%) cases. Stromal CD10 showed
positive correlation with tumour grade, HER2-neu (P = .000), and ki67 (P = .027), negative correlation with ER and PR.
Conclusions. Hence CD10 expression correlated strongly with well-established negative prognostic markers, that is, HER2-neu
and ki67 positivity, ER/PR negativity, and higher tumour grade, thus indicating that CD10 can be used as independent marker
indicating poor prognosis and can be used as target for the development of novel therapies.
1.Introduction
Breast cancer is one of the commonest cancers among
women globally. Each individual tumour varies with respect
to invasive and metastatic potential as well as growth rate.
The prognosis of a given lesion is related to member and
types of oncogene activated. Various markers have been
used to study the oncogene expression or ampliﬁcation.
The clinical course of the neoplasm can be altered by
directing therapy against overexpressed oncogenes. Well-
established prognostic factors including stage of tumour,
histological grade, lymph node status, ER/PR status, and
HER2-neu are routinely studied in every case of breast
cancer. Stromal markers are now emerging as novel markers
in assessing the prognosis of invasive breast cancer and have
not been studied extensively till date. Stroma plays a key
role in modulating tumour invasion and metastasis. A better
understanding ofstromal contribution tocancerprogression
will identify speciﬁc signals that promote growth, dediﬀer-
entiation, invasion, and ectopic survival of tumour cells and
eventually result in the identiﬁcation of new therapeutic
targets for future treatment [1]. This justiﬁes the study of
new stromal marker CD10in the prognosis ofinvasive breast
carcinoma.
CD10 is a zinc-dependent metalloproteinase that has
been called common acute lymphoblastic antigen (CALLA).
It is frequently expressed in bone marrow lymphoid stem
cells, pro-B lymphoblasts, mature neutrophils, various lym-
phoma subtypes, renal cell carcinoma and endometrial
stromal sarcoma. Several reports indicated that stromal
CD10 expression is associated with biological aggressiveness
in various epithelial malignancies [2–6].
To date, only one study has correlated the expression
of CD10 with well-known prognostic markers of breast
carcinoma; however, its correlation with Ki67 is still not
studied. The aims of this study were, (1) to estimate the
frequency of expression of stromal CD10 in invasive breast
carcinomas and (2) to assess prognostic signiﬁcance of
stromal CD10 expression and its correlation with known
prognostic markers of breast carcinoma.2 International Journal of Breast Cancer
30 4 2008
Figure 1: Fibroadenoma in this ﬁgure shows highlighted myoep-
ithelial cells by CD10. There was no expression of CD10 in normal
ductal cells, ﬁbroblasts.
2.Materialsand Methods
The present study was conducted in the department of
pathology and surgery.
Cases of breast lump were referred to pathology depart-
ment from surgery clinics for FNAC during the study
period, that is, from November 2007 to March 2009. Trucut
biopsy was performed on cytologically provencases of breast
carcinoma, and the following parameters were noted:
(1) age,
(2) family history,
(3) clinical presentations-lump/pain/nipple discharge,
(4) clinical TNM staging.
Study group comprised ﬁfty cases of breast carcinoma
diagnosed on trucut biopsy. Trucut biopsy was performed
on patients using 14-gauge needle of length 3 inches, under
full aseptic precautions, using local anaesthesia. Tissue from
trucut biopsy was processed, paraﬃn blocks were prepared,
and subsequently six slides were cut from each.
Slide1: Stained with haematoxylin and eosin.
Slide 2: Immunohistochemistry for estrogen receptor (Diag-
nostic biosystems ER, 1D5 clone), dilution 1:50.
Slide 3: Immunohistochemistry for progesterone receptor
(Diagnostic biosystems PR (hPRa2 + hPRa3 clone),
dilution 1:50.
Slide 4: Immunohistochemistry for HER2-neu (Diagnostic
biosystems HER2-neu, CD11 clone). Dilution 1:50.
Slide 5: Immunohistochemistry for CD10 (Diagnostic bio-
systems CD10 (56C6 clone), dilution 1:30. Sections
of ﬁbroadenoma were put up as control (Figure 1).
Slide 6: Immunohistochemistry forki-67Ki67(MIB-1clone)
DAKO,mouse monoclonal antibody, dilution1:500.
LSABC kit was used as the detection system. ER and PR
stainscoringwasdonebyquickscore.HER2-neuscoringwas
done as in (Table 1)C D 1 0s c o r i n gw a sd o n ea si n( T a b l e2).
Table 1: HER2-neu scoring.
Staining pattern Score HER2-neu
overexpression
No staining or membrane
staining <10% tumor cells 0n e g a t i v e
Faint/perceptible membrane
staining in >10% tumor cells 1n e g a t i v e
Weak to moderate complete
membrane staining in >10%
tumor cells
2w e a k
Strong complete membrane
staining in >10% tumor cells 3s t r o n g
Table 2: CD10 scoring.
Score CD10 Staining
Negative <10% stromal positive cells/core
Weak 10–30% stromal positive cells/core
Strong >30% stromal positive cells/core
Statistical analysis was done, and P values less than .05
were considered signiﬁcant.
3.Results
Mean age of patients was 48.5 years (range 30–80 years).
Most of our cases belonged to T4 category (21/50; 42%)
followed by T2 category (15/50; 30%) and T1 category
(14/50; 28%). Inﬁltrating ductal carcinoma, not otherwise
speciﬁed (NOS), the comprised majority of our study
population (47/50; 94%) followed by two cases (4%) of
mucinous carcinoma and one case (2%)of inﬁltrating ductal
carcinoma with extensive in situ component. Bloom and
Richardson grading was performed on all cases except one,
which was IDC with extensive in situ component. Most
patients 26/49 (53.06%) in our study belonged to grade
3, while 17/49 (34.69%) belonged to grade 2 and 6/49
(12.24%) belonged to grade 1. CD10 immunostaining was
done on all 50 cases. No stromal expression was detected in
the normal breast although the Nonneoplastic myoepithelial
cells, whenever present, served as a built-in positive control
for CD10 (Figure 2). There was no expression of CD10
in normal ductal cells, ﬁbroblasts, and adipose cells. The
stainingwasscoredasnegative,weak,andstrongasdescribed
in Table 2.
CD10 was found to be positive in 80% of cases (40/50),
out of which 16 (40%) showed weak immunoreactivity
(Figure 3) whereas strong positivity (Figure 4)w a so b s e r v e d
in 24 cases (60%) which included one case of IDC with
extensive in situ component. Extensive in situ component
was clearly highlighted by strong positivity of CD10 in
myoepithelialcells.Thesamecasealsoshowedfociofstromal
CD10 positivity indicating invasion.International Journal of Breast Cancer 3
Figure 2: Nonneoplastic myoepithelial cells, whenever present,
were used as built-in positive control.
Figure 3: Weak CD10 stromal staining.
Table 3: Correlation of CD10 with ER.
CD10 ER Negative ER Positive Total
Negative 7 (70%) 3 (30%) 10
Weak 7 (43.75%) 9 (56.25%) 16
Strong 21 (87.5%) 3 (12.5%) 24
Total 35 15 50
3.1. Expression of Stromal CD10 in Breast Cancer and
Correlations with Other Clinicopathological Data. Ap o s i t i v e
correlation was observed between CD10 and tumour grade,
h o w e v e ri tw a sn o ts t a t i s t i c a l l ys i g n i ﬁ c a n t( P = .139).
Percentage positivity of strong CD10 increased from 50% to
64.71% in T2 to T4 category, butit could not reach statistical
signiﬁcance (P = .558). With increasing CD10 positivity
from weak to strong, ER negativity increased from 43.75%
to 87.5%. (P = .188) (Table 3).
Similarly CD10 was found to have a negative correlation
withPRhoweveritwasnotstatisticallysigniﬁcant.Astrongly
positive statistical signiﬁcance was found between CD10
positivity and HER2-neu (P = .000) (Table 4).
A positive statistical signiﬁcance was found between
CD10 positivity and Ki67 (P = .027) (Table 5).
Figure 4: Strong CD10 stromal staining.
Table 4: Correlation of CD10 with HER2-neu.
HER2-neu CD10 negative CD10 positive Total
Weak Strong
Negative 8 9 3 20
Score 2 1 3 4 8
Score 3 1 4 17 22
Total 10 15 25 50
P = .000.
Table 5: Correlation of CD10 with Ki67.
CD10 Ki67 negative Ki67 positive Total
Negative 2 8 10
Weak 1 14 15
Strong 25 25
Total 3 47 50
P = .027.
4.Discussion
CD10 is a cell surface zinc-dependent metalloproteinase.
Matrix metalloproteinases are a family of metallopeptidases
that cleave the protein components of extracellular matrix
and thereby play a central role in tissue remodelling. A better
understanding ofstromal contributionto cancerprogression
will identify speciﬁc signals that promote growth, dediﬀer-
entiation, invasion, and ectopic survival of tumour cells and
eventually result in identiﬁcation of new therapeutic targets
forfuturetreatment[1].AccordingtothestudybyMakretsov
et al. [4], stromal CD10 is positive in 79% of patients,
with weak immunoreactivity in 40% cases whereas strong
positivity was observed in 39% cases. In our study also,
CD10 was positive in 80% of patients similar to the above
study with strong stromal positivity in 60% of cases and
weak immunoreactivity in40%ofcases. Morecases ofstrong4 International Journal of Breast Cancer
CD10 were present in our study as most of our patients had
grade 3 tumours whereas in a study by Makretsov et al. the
majority of the patients had grade 2 tumours. In a study by
Iwaya et al. [3], no statistically signiﬁcant correlation was
observed between CD10 and tumour grade (P = .1613).
According to study by Makretsov et al., percentage positivity
of strong CD10 increased from 29% to 59% in grade 1 to
grade3.Ourresultsalsoshowedverysimilartrends.Onecase
in our study was of IDC with extensive in situ component.
Extensive in situ component was clearly highlighted by
strong positivity of CD10 in myoepithelial cells. The same
case also showed foci of strong stromal CD10 positivity
indicating invasion. Martinez et al. proved in their study
that there is a relationship between the presence of extensive
intraductal component and the risk of local recurrence for
patient with invasive breast cancer treated with conservative
surgery and radiation surgery [7]. Extensive intraductal
component constitutesa very important predictive factor for
local breast recurrence. Hence CD10 can help as a useful
marker in identifying invasion in problematic cases with
in situ component. Makretsov et al. [4] showed statistically
signiﬁcant correlation between strong CD10 staining and ER
negativity (P−.002).Similarly in ourstudy, CD10wasfound
to have good negative correlation with ER; however, it was
not statistically signiﬁcant probably due to less number of
cases in our study. Makretsov et al. [4], found no statistical
signiﬁcance was found between stromal CD10 expression
and PR status (P>. 05).This is in accordance with our study,
where CD10 was found to have good negative correlation
with PR, however it was not statistically signiﬁcant (P>. 05).
A strongly positive statistical signiﬁcance was found between
CD10 positivity and HER2-neu (P = .000) in our study.
On the contrary Makretsov et al. [4], found no statistically
signiﬁcantcorrelationbetweenstromal CD10expressionand
HER2-neu status of tumour (P>. 05). However since only
one study has given the correlation with stromal CD10
expression and HER2-neu expression of tumour till date,
further studies are needed to ﬁrmly establish the correlation.
A positive statistical signiﬁcance was found between CD10
positivity and Ki67 (P = .027) No study till date has
correlated with stromal CD10 and ki67.
To conclude CD10 expression correlated strongly with
well-established negative prognostic marker that is, HER2-
neuandki67positivity,ER/PRnegativity,andhighertumour
grade. thus indicating, CD10 can be used as independent
marker indicating poor prognosis and can be used as target
for development of novel therapies.
Thus, we suggest that core needle biopsy should be an
important part of preoperative workup and along with the
traditional panel of markers, CD10 can be put up routinely
as a prognostic marker in all breast cancer patients.
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